Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada’s sentinel surveillance network, January 2014

D M Skowronski; C Chambers; S Sabaiduc; G De Serres; J A Dickinson; A L Winter; K Fonseca; J B Gubbay; H Charest; M Petric; M Krajden; S M Mahmud; P Van Caeseele; T L Kwindt; A Eshaghi; N Bastien; Y Li

doi:10.2807/1560-7917.ES2014.19.5.20690

Rapid communications Open Access

Like 0

Download

Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada’s sentinel surveillance network, January 2014
D M Skowronski^1,2 , C Chambers¹ , S Sabaiduc¹ , G De Serres^3,4,5 , J A Dickinson⁶ , A L Winter⁷ , K Fonseca^6,8 , J B Gubbay^7,9 , H Charest³ , M Petric^1,2 , M Krajden^1,2 , S M Mahmud^10,11 , P Van Caeseele^11,12 , T L Kwindt^1,2 , A Eshaghi⁷ , N Bastien¹³ , Y Li^11,13
View Affiliations Hide Affiliations

Affiliations: ¹ British Columbia Centre for Disease Control, Vancouver, Canada ² University of British Columbia, Vancouver, Canada ³ Institut National de Santé Publique du Québec (National Institute of Health of Quebec), Québec, Canada ⁴ Laval University, Quebec, Canada ⁵ Centre Hospitalier Universitaire de Québec (University Hospital Centre of Quebec), Québec, Canada ⁶ University of Calgary, Calgary, Canada ⁷ Public Health Ontario, Toronto, Canada ⁸ Alberta Provincial Laboratory, Calgary, Canada ⁹ University of Toronto, Toronto, Canada ¹⁰ Winnipeg Regional Health Authority, Winnipeg, Canada ¹¹ University of Manitoba, Winnipeg, Canada ¹² Cadham Provincial Laboratory, Winnipeg, Canada ¹³ National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

Correspondence:
D Skowronski
danuta.skowronski bccdc.ca
View Citation Hide Citation

Citation style for this article: Skowronski D M, Chambers C, Sabaiduc S, De Serres G, Dickinson J A, Winter A L, Fonseca K, Gubbay J B, Charest H, Petric M, Krajden M, Mahmud S M, Van Caeseele P, Kwindt T L, Eshaghi A, Bastien N, Li Y. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada’s sentinel surveillance network, January 2014. Euro Surveill. 2014;19(5):pii=20690. https://doi.org/10.2807/1560-7917.ES2014.19.5.20690 Received: 29 Jan 2014

Abstract

The 2013/14 influenza season to date in Canada has been characterised by predominant (90%) A(H1N1)pdm09 activity. Vaccine effectiveness (VE) was assessed in January 2014 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically-attended laboratory-confirmed influenza A(H1N1)pdm09 infection was 74% (95% CI: 58-83). Relative to vaccine, A(H1N1)pdm09 viruses were antigenically similar and genetically well conserved, with most showing just three mutations across the 50 amino acids comprising antigenic sites of the haemagglutinin protein. .